惠州市锦好医疗科技股份有限公司（以下简称"公司"）为进一步完善公司法 人治理结构，建立、健全公司长效激励约束机制，吸引和留住优秀人才，充分调 动公司（含控股子公司、分公司，下同）董事、高级管理人员及核心员工的积极 性，有效地将股东利益、公司利益和核心团队个人利益结合在一起，使各方共同 关注公司的长远发展，确保公司发展战略和经营目标的实现，在充分保障股东利 益的前提下，按照收益与贡献对等的原则，公司制定了《惠州市锦好医疗科技股 份有限公司 2025 年限制性股票激励计划（草案）》（以下简称"本激励计划"或 《激励计划（草案）》）。 证券代码：872925 证券简称：锦好医疗 公告编号：2025-043 惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划实施考核管理办法 本公司及董事会全体成员保证本公告内容的真实、准确和完整，没有任何虚 假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 为保证本激励计划的顺利进行，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公 司股权激励管理办法》（以下简称 ...

（草案） 惠州市锦好医疗科技股份有限公司 二〇二五年五月 声 明 本公司及全体董事、监事、高级管理人员保证本激励计划相关信息披露不存 在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担个别 及连带责任。 证券代码：872925 证券简称：锦好医疗 公告编号：2025-040 惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划 自本激励计划公告当日至激励对象获授的限制性股票完成授予登记期间，若 公司发生资本公积转增股本、派发股票红利、股份拆细或缩股、配股等事宜，限 制性股票的数量及所涉及的标的股票总数将做相应的调整。 四、本激励计划限制性股票的首次及预留授予价格为 8.80 元/股。 自本激励计划公告当日至激励对象获授的限制性股票完成授予登记期间，若 公司发生资本公积转增股本、派发股票红利、股份拆细或缩股、配股、派息等事 宜，限制性股票的授予价格将做相应的调整。 2 本公司所有激励对象承诺，若公司因信息披露文件中有虚假记载、误导性陈 述或者重大遗漏，导致不符合授予权益或行使权益安排的，激励对象应当自相关 信息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由参与本激 励计划所 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2025-044 惠州市锦好医疗科技股份有限公司 关于召开 2025 年第一次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第一次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 2025 年 5 月 12 日，公司召开第三届董事会第十一次会议审议通过《关于提 请召开 2025 年第一次临时股东会的议案》。 （三）会议召开的合法合规性 本次股东会的召集符合《公司法》等有关法律、法规及《公司章程》的规定， 无需相关部门批准或履行其他程序。 （四）会议召开方式 本次会议采用现场投票、网络投票和其他投票方式相结合方式召开。 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现 重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 5 月 29 日 15:00。 2、网络投票起止时间：2 ...

法律意见书 北京大成（广州）律师事务所 关于惠州市锦好医疗科技股份有限公司 2025 年限制性股票激励计划（草案）的 法律意见书 www.dentons.com 广州市天河区珠江东路 6 号广州周大福金融中心 14 层、15 层 电话：+86 20 8527 7000 传真：+86 20 8527 7002 二〇二 五 年 五 月 目 录 | 一、公司实行股权激励计划的条件 5 | | --- | | 二、本次股权激励计划的主要内容 6 | | 三、本次股权激励计划涉及的法定程序 13 | | 四、本次股权激励计划激励对象的确定 15 | | 五、本次股权激励计划的信息披露 15 | | 六、公司没有为激励对象提供财务资助 15 | | 七、本次股权激励计划不存在明显损害上市公司及股东利益的情形 15 | | 八、本次股权激励计划存在需要关联董事回避表决的情形 16 | | 九、结论意见 16 | 法律意见书 法律意见书 致：惠州市锦好医疗科技股份有限公司 北京大成（广州）律师事务所（以下简称"本所"）接受惠州市锦好医疗科 技股份有限公司（以下简称"锦好医疗"或者"公司"）的委托，担任锦好医疗 实施 2025 ...

证券代码：872925 证券简称：锦好医疗 公告编号：2025-039 惠州市锦好医疗科技股份有限公司 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 12 日 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯方式相结合 4.发出董事会会议通知的时间和方式：2025 年 5 月 9 日以书面方式发出 5.会议主持人：王敏先生 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开程序符合《公司法》、《公司章程》和《董事会议事规 则》的相关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事李忠轩因工作原因以通讯方式参与表决。 董事郑能恒因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于<惠州市锦好医疗科技股份有限公司 2025 年限制性股票激 励计划（草案）>的议案》 1.议案内容 ...

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry [6] Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11] - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13] - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16] Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 industry indices [2][11] - The year-to-date performance shows a 1.19% increase, ranking 15th among the indices [13] 2. Key Company Announcements - Notable companies such as Kellytai, BGI Genomics, and Dongfang Bio have reported varying financial results, with some showing declines in net profit [21] 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22] - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22] - The report suggests that the innovative drug sector is entering a phase of realization of results, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22] 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%) and Haichuang Pharmaceutical (+25.85%), while the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20]

Investment Rating - The report maintains a "Recommended" rating for the healthcare sector [6]. Core Insights - The pharmaceutical sector has shown a slight underperformance compared to the CSI 300 index, with a 1.50% increase from April 28 to May 9, 2025, lagging by 0.06 percentage points [2][11]. - Year-to-date, the pharmaceutical index has risen by 1.19%, outperforming the CSI 300 by 3.45 percentage points [13]. - As of May 9, 2025, the valuation of the pharmaceutical sector stands at 26.54 times (TTM), with a premium of 141.81% over the CSI 300 [16]. Summary by Sections 1. Market Performance Review - The pharmaceutical sector's performance from April 28 to May 9, 2025, was a 1.50% increase, ranking 16th among 31 sectors [2][11]. - The year-to-date performance shows a 1.19% increase, ranking 15th among the sectors [13]. 2. Key Company Announcements - Key companies such as Kelly Tai, BGI Genomics, and Dongfang Bio reported varying financial results, with some showing significant declines in net profit [21]. 3. Industry Perspective - The pharmaceutical sector's revenue decreased by 0.99% in 2024, with net profit down by 12.97%. In Q1 2025, revenue fell by 4.78%, and net profit decreased by 12.21% [4][22]. - The report highlights a shift in market focus from earnings to fundamental changes in the industry and companies, with optimism surrounding innovative drugs, international expansion, and the clearing of centralized procurement impacts [4][22]. - The report suggests that the innovative drug sector is entering a phase of realization, with significant R&D progress and minimal impact from trade wars, making it a key investment theme for 2025 [4][22]. 4. Stock Performance - The top-performing stocks included Changshan Pharmaceutical (+26.29%), Haichuang Pharmaceutical (+25.85%), and Jinhao Medical (+25.32%) [3][20]. - Conversely, the worst performers included Puli Retreat (-69.88%) and ST Suwu (-31.39%) [3][20].

中信建投证券股份有限公司 关于惠州市锦好医疗科技股份有限公司 向不特定合格投资者公开发行股票之保荐工作总结报告书 中信建投证券股份有限公司（以下简称"中信建投"或"保荐机构"）作为 惠州市锦好医疗科技股份有限公司（以下简称"锦好医疗"、"公司"或"发行 人"）向不特定合格投资者公开发行股票（以下简称"本次发行"）的保荐机构， 履行持续督导职责期限至 2024 年 12 月 31 日。目前，本次发行持续督导期限已 经届满，根据《证券发行上市保荐业务管理办法》《北京证券交易所证券发行上 市保荐业务管理细则》《北京证券交易所股票上市规则》等法规和规范性文件要 求，保荐机构出具本保荐工作总结报告书。 二、保荐工作概述 （一）尽职推荐工作 发行人名称 惠州市锦好医疗科技股份有限公司 证券代码 872925 注册资本 9,768.6643 万元 注册地址 惠州仲恺高新区四环南路（惠环段）207 号锦好智慧医疗产业 园 主要办公地址 惠州仲恺高新区四环南路（惠环段）207 号锦好智慧医疗产业 园 法定代表人 王敏 实际控制人 王敏、王芳 联系电话 0752-3266781 本次证券发行类型 向不特定合格投资者公开发行股票并 ...

Market Overview - The Shanghai Composite Index closed at 3328.43 points, above the six-month moving average, with an increase of 0.37% [1] - The total trading volume of A-shares reached 12152.25 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 144 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - JinHao Medical: 26.73% - SuAo Sensor: 19.75% - HuaWu Co., Ltd.: 17.98% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Aerospace Intelligent Manufacturing - Changqing Technology - China Merchants Highway [1] Performance of Selected Stocks - JinHao Medical: Today's increase of 29.96% with a turnover rate of 23.69% [1] - SuAo Sensor: Increased by 20.05% with a turnover rate of 8.96% [1] - HuaWu Co., Ltd.: Increased by 19.94% with a turnover rate of 20.89% [1] Additional Notable Stocks - Other stocks with notable performance include: - JiuDing Investment: 9.97% increase, 7.73% turnover rate - Arrow Home: 10.02% increase, 8.27% turnover rate - Construction Industry: 10.01% increase, 13.40% turnover rate [1]

Stock Performance - Several stocks have shown significant gains, with notable performances including: - 恒天海龙 with a 10.07% increase over two days [2] - 晨曦航空 achieving a 19.96% rise on its first board [3] - 通易航天 with a remarkable 29.96% increase on its first board [3] - 新坐标 maintaining a 10.01% increase over four days [5] - 全筑股份 also showing a 10.00% increase over four days [9] Industry Trends - The robotics sector is gaining traction, with multiple companies experiencing stock price increases attributed to advancements in robotic technology and applications [4][5][7] - The AI computing industry is showing strong performance, as indicated by the positive financial results from companies in this sector, suggesting a sustained high level of industry activity [8] - The brain-computer interface (BCI) technology is gaining attention following FDA approval for Neuralink's device, which is aimed at aiding patients with severe communication disabilities [11] - The chemical industry is experiencing volatility in product prices, drawing market interest towards related companies [13] - The semiconductor industry is benefiting from increased investment and support for domestic high-end lithography machines, which is expected to boost the semiconductor equipment supply chain [16] - The real estate sector is reacting positively to the People's Bank of China's decision to lower housing loan interest rates, which is likely to stimulate market activity [18] Market Reactions - Stocks related to the ride-hailing industry are responding positively to the news of a partnership between autonomous driving company 小马智行 and Uber, with significant stock price increases observed [20][21] - The food and beverage sector is also seeing positive movements, influenced by the central bank's announcement of a new loan program aimed at boosting consumer spending [22][24] - The financial sector is reacting to the People's Bank of China's announcement of a series of monetary policy measures, including a reserve requirement ratio cut and interest rate adjustments [25][26]